All Work

Jon C. Ogg

Twitter Operating Profit Meets Lower User Growth Metrics

courtesy of TwitterTwitter, Inc. (NYSE: TWTR) is out with earnings, and the numbers look very impressive on the surface. The problem is that there are some serious caveats for growth ahead and user metrics.…

Jon C. Ogg · 13 years ago

The Return of the NFL Player IPOs — Really

ThinkstockThe athlete IPO talk is back. In fact, they may be back in business. Two issues are driving the chatter here, and it is not that the Super Bowl was a crowd killer. News…

Jon C. Ogg · 13 years ago

Can CBS Make You Watch Thursday Night Football?

ThinkstockA news break is out from multiple sources, showing that CBS Corp. (NYSE: CBS) will produce a full slate of 16 NFL games. The problem is that this is the Thursday Night Football package.…

Jon C. Ogg · 13 years ago

ADP Tries Blaming Weather for Lower Payrolls

ThinkstockWednesday’s ADP Private Sector Payrolls report showed a gain of 175,000 in January. Dow Jones was calling for 189,000 and Bloomberg was calling for 170,000. While there has to be some merit to the…

Jon C. Ogg · 13 years ago

Despite Size, Gilead Keeps Growing and Growing

ThinkstockGilead Sciences Inc. (NASDAQ: GILD) is the biggest biotech company in America, and it is one of the top performers for 2013. Despite having a market cap of well over $100 billion now, this…

Jon C. Ogg · 13 years ago

Two Very Different Analyst Takes on Zynga: Buy vs. Sell

courtesy of ZyngaZynga, Inc. (NASDAQ: ZNGA) is a very controversial company and is really sort of a battleground stock. There are big bulls, and big bears. Its future is still far from certain. Shares…

Jon C. Ogg · 13 years ago

Is J.C. Penney Stock Really Only Worth $3?

courtesy J.C. Penney Co. Inc.J.C. Penney Co. (NYSE: JCP) does not exactly have that many fans and champions on Wall Street nor on Main Street these days. The stock may be only at $5.68…

Jon C. Ogg · 13 years ago

IBS Drug Success: The Fast and the Furiex

Usually when you see stocks double, it is based on a buyout or a major partnership development. That is not the case for Furiex Pharmaceuticals, which soared on news of positive top-line study results…

Jon C. Ogg · 13 years ago

Will Petrobras Stock Break Under $10?

Petrobras is supposed to be a great oil giant, with vase proven and probable reserves, and with a vast opportunity in Brazil. The problem is that nothing seems to go right for the Petrobras…

Jon C. Ogg · 13 years ago